- Total News Sources
- 14
- Left
- 10
- Center
- 3
- Right
- 1
- Unrated
- 0
- Last Updated
- 74 days ago
- Bias Distribution
- 71% Left
Pfizer Launches Platform, Competes with Eli Lilly
Pfizer has launched a direct-to-consumer (D2C) digital platform, PfizerForAll, aimed at patients with migraines and respiratory ailments, including COVID-19. This move puts Pfizer in direct competition with Eli Lilly, which has recently introduced a new, more affordable version of its weight-loss drug Zepbound in single-dose vials, priced at about half the cost of its previous offerings. Lilly's strategy aims to overcome supply chain issues related to its complex auto-injector pens and to compete with compounded versions of GLP-1 drugs. The new pricing structure for Zepbound has led to a significant decline in shares of competitors like Viking Therapeutics and Zealand Pharma. Lilly's initiative is expected to increase consumer access and affordability, addressing a critical gap for patients without insurance coverage. Analysts consider Lilly's move a strategic challenge to the existing compounded drug market, potentially increasing market pressures on similar players such as Hims&Hers Health.
- Total News Sources
- 14
- Left
- 10
- Center
- 3
- Right
- 1
- Unrated
- 0
- Last Updated
- 74 days ago
- Bias Distribution
- 71% Left
Open Story
Timeline
Analyze and predict the
development of events
Related Topics
Stay in the know
Get the latest news, exclusive insights, and curated content delivered straight to your inbox.